US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.99

-2.2085-4.89%

Post-market: 42.990.00000.00%16:10 EDT

Volume:3K

Turnover:133.25K

Market Cap:32.24M

PE:- -

High:45.58

Open:45.58

Low:42.95

Close:45.20

52wk High:45.58

52wk Low:31.44

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.12

T/O Rate:0.40%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ligand Pharmaceuticals Incorporated - 2026 Adj EPS Guidance $9 to $9.50, Previously $8.50 to $9.50

THOMSON REUTERS

Ligand Pharmaceuticals Q2 EPS USD 2.22

THOMSON REUTERS

Natera CFO Michael Burkes Brophy Disposes of 795 Common Shares Worth $215,449.79

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Natera Seeks Japan PMDA Approval for Signatera Test in Muscle-Invasive Bladder Cancer

Ligand CLO, Secretary Andrew Reardon Reports Disposal of 5,000 Common Shares Worth $1.44 Million

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Guardant Health is Maintained at Overweight by Morgan Stanley

Adaptive Biotechnologies is Maintained at Overweight by Piper Sandler

U.S. Research Roundup-Cloudflare, Replimune, Walmart

Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open

Simply Wall St.

AI-Driven Lung Cancer Screening Advances Precision Medicine, Boosting Opportunities for TH MEDICAL-B (02697)

Asymchem shares surge 5% on plan to inject 1.05 billion yuan into biotech subsidiary

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176

ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)

ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates

GeneDx Q2 Revenue Beats Analyst Estimates

Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/HELX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.9867,"timestamp":1791316800000,"preClose":45.1952,"halted":0,"volume":3036,"hourTrading":{"tag":"盘后","latestPrice":42.9867,"preClose":42.9867,"latestTime":"16:10 EDT","volume":8,"amount":343.963504,"timestamp":1791317405226,"change":0,"changeRate":0,"amplitude":0.000542},"delay":0,"changeRate":-0.04886580875845224,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Post-Mkt","change":-2.2085,"latestTime":"10-06 18:31:03 EDT","open":45.58,"high":45.58,"low":42.95,"amount":133250,"amplitude":0.058192,"askPrice":46.98,"askSize":1,"bidPrice":22.47,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791331200000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":45.1952,"sharesOutstanding":650000,"nav":43.859,"aum":32894030.1,"dividendRate":0.003362,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.9867,"preClose":42.9867,"latestTime":"16:10 EDT","volume":8,"amount":343.963504,"timestamp":1791317405226,"change":0,"changeRate":0,"amplitude":0.000542},"volumeRatio":0.119903,"impliedVol":0.1194,"impliedVolPercentile":0.4183},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.119903,"shares":750000,"dividePrice":0.1445,"high":45.58,"amplitude":0.058192,"preClose":45.1952,"low":42.95,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":42.9867,"committee":0.980198,"eps":0,"divideRate":0.003362,"volume":3036,"delay":0,"ttmEps":0,"open":45.58,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":44.4008,"twentyDayClose":41.6426,"sixtyDayClose":39.7282},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657763390","title":"Ligand Pharmaceuticals Incorporated - 2026 Adj EPS Guidance $9 to $9.50, Previously $8.50 to $9.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763390?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX7054G2:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","BK4139","HELX","LU0566484027.USD","LU1559883803.SGD","IE0009354923.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680486","title":"Ligand Pharmaceuticals Q2 EPS USD 2.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680486?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX7054G2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","BK4139","LU0566484027.USD","LU1559883803.SGD","BK4007","IE0009354923.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508493","title":"Natera CFO Michael Burkes Brophy Disposes of 795 Common Shares Worth $215,449.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508493","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508493?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:35","pubTimestamp":1785980152,"startTime":"0","endTime":"0","summary":"Natera CFO Michael Burkes Brophy disposes of 795 common shares worth $215,449.79Natera CFO Michael Burkes Brophy sold 795 common shares on Aug. 3-4.Sales priced at USD 267.99 to USD 274.22 per share.H","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6sQPKL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera CFO Michael Burkes Brophy Disposes of 795 Common Shares Worth $215,449.79","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4139","LU0106261612.USD","LU2324357040.USD","LU2065169927.USD","LU2065171402.SGD","LU0012050646.USD","LU0963586101.USD","LU1988902786.USD","LU2065731478.USD","LU1064131342.USD","LU0345770993.USD","GNOM","LU2264538146.SGD","LU2065170008.USD","HELX","LU0053671581.USD","LU0345770308.USD","NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4551","PTH","GH","LU0889565916.HKD","GNOM","BK4196","BK4585","LU0109394709.USD","BK4588","GDOC","GNMX","FFOX","BK4535","HELX","LU0320765992.SGD","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657208075","title":"Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657208075","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657208075?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:08","pubTimestamp":1785960518,"startTime":"0","endTime":"0","summary":"Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlookOverviewUS dermatology drug maker's Q2 product revenue rose 59% yr/yr, driven by ZORYVE demandCompany raised 2026 full-year net p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","ARQT","LU2065169927.USD","LU2065171402.SGD","PSCH","LU2065170008.USD","ACAD","HELX","LU2065171311.SGD","BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543991","title":"United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543991","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543991?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:38","pubTimestamp":1785926324,"startTime":"0","endTime":"0","summary":"United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weaknessOverviewRare disease drugmaker's Q2 revenue fell 2% yr/yr, missing analyst expectationsQ2 net income rose 8% yr/yr; diluted E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","PSCH","KRYS","LFSC","BK4532","TVTX","LU1699723380.USD","LU1571399168.USD","BK4139","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510294","title":"Natera Seeks Japan PMDA Approval for Signatera Test in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510294","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510294?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:03","pubTimestamp":1785924184,"startTime":"0","endTime":"0","summary":"Natera seeks Japan PMDA approval for Signatera test in muscle-invasive bladder cancerNatera filed Signatera with Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLbyDBmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2264538146.SGD","LU0345770993.USD","BK4139","LU2065731478.USD","HELX","LU0345770308.USD","LU2065171311.SGD","LU0106261612.USD","LU0012050646.USD","NTRA","LU1064131342.USD","LU1988902786.USD","LU2065170008.USD","LU0053671581.USD","LU0963586101.USD","LU2324357040.USD","LU2065169927.USD","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657187598","title":"Ligand CLO, Secretary Andrew Reardon Reports Disposal of 5,000 Common Shares Worth $1.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657187598","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657187598?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:43","pubTimestamp":1785883420,"startTime":"0","endTime":"0","summary":"Ligand CLO, Secretary Andrew Reardon reports disposal of 5,000 common shares worth $1.44 millionLigand Pharmaceuticals CLO and Secretary Andrew Reardon exercised employee stock options for 5,000 share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL7VGDr6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ligand CLO, Secretary Andrew Reardon Reports Disposal of 5,000 Common Shares Worth $1.44 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","HELX","BK4007","BK4139","IE0009354923.USD","LU1559883803.SGD","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657404561","title":"Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657404561","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657404561?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:18","pubTimestamp":1785874711,"startTime":"0","endTime":"0","summary":"Ultragenyx Q2 revenue rises 28% to record high, net loss narrowsOverviewUS biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company historyNet loss for Q2 narrowed yr/yr, with lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N441167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","RARE","BK4007","PSCH","KRYS","HELX","BK4588","RYTM","MEDI","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556059","title":"Guardant Health is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556059?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:44","pubTimestamp":1785847440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","GNMX","BK4585","PTH","LFSC","FFOX","GNOM","EKG","BK4588","GDOC","BK4535","LU0889565916.HKD","GH","LU0109394709.USD","BK4551","HELX","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556333","title":"Adaptive Biotechnologies is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556333?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:22","pubTimestamp":1785846120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656387125","title":"U.S. Research Roundup-Cloudflare, Replimune, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2656387125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656387125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 15:22","pubTimestamp":1785828137,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, WalmartAug 4 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cloudflare, Repl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4410IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","CRS","ABG","CLX","NET","VPU","DDOG","ITB","FICO","CI","CNC","ADPT","IVEP","ALHC","FBNC","EKG","APG","ALNY","HELX","CEG","ARXS","IDU","DXCM","NLR","EVER","NETG","WCBR","BBY","CMG","AVA","CRWU","LIFE","AMRC","DUOL","AGCO","UPW","DHI","ARCB","BOW","SMRF","ECHO","CBOE","FBLG","BLZE","CRWV","FTH","BWXT","AN","BNY","AZO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656753914","title":"Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open","url":"https://stock-news.laohu8.com/highlight/detail?id=2656753914","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656753914?lang=en_us&edition=fundamental","pubTime":"2026-08-04 15:22","pubTimestamp":1785828122,"startTime":"0","endTime":"0","summary":"Guardant Health filed a universal shelf registration statement, allowing it to issue various securities in the future.\nThe filing gives the company flexibility to raise capital through debt, equity, or hybrid instruments as needed.\nThis development could be used to support future financing, potential acquisitions, or balance sheet adjustments.\n\nGuardant Health, listed as NasdaqGS:GH, now has formal flexibility to raise funds through a range of securities. The stock last closed at $158.83 and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-filed-a-shelf-registration-to-keep-future","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-filed-a-shelf-registration-to-keep-future","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FFOX","LU0889565916.HKD","BK4588","GH","BK4196","HELX","LFSC","LU0320765992.SGD","LU0109394709.USD","BK4535","BK4551","GNOM","GNMX","BK4585","EKG","GDOC","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103326040","title":"AI-Driven Lung Cancer Screening Advances Precision Medicine, Boosting Opportunities for TH MEDICAL-B (02697)","url":"https://stock-news.laohu8.com/highlight/detail?id=1103326040","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103326040?lang=en_us&edition=fundamental","pubTime":"2026-08-04 13:03","pubTimestamp":1785819824,"startTime":"0","endTime":"0","summary":"The integration of cutting-edge technologies like artificial intelligence and medical robotics into clinical diagnostics is driving breakthroughs in early lung cancer screening and precision...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XT","SYNB","VTHR","AIPO","BMED","HELX","CHAT","QTOC","KOMP","GDOC","GNMX","DTEC","ARTY","WDNA","IDNA","AGIX","02697","TYNE","159891","HTEC","GNOM","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121045193","title":"Asymchem shares surge 5% on plan to inject 1.05 billion yuan into biotech subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=1121045193","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121045193?lang=en_us&edition=fundamental","pubTime":"2026-08-04 09:28","pubTimestamp":1785806898,"startTime":"0","endTime":"0","summary":"Asymchem (06821) opened more than 5% higher on the Hong Kong Stock Exchange on Monday, with shares trading up 5.5% to HK$115 as of press time, on a turnover of HK$3.197 million.The company, known as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328615791.USD","002821","HELX","BK4585","BK4588","BK0132","VXUS","06821","BK1191","WDNA","KCAI","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300573","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300573","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300573?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:27","pubTimestamp":1785796048,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky disposes of 1,299 common shares for $31,176Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sold 1,299 common shares on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLbC3PX5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302838","title":"ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302838","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302838?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:40","pubTimestamp":1785789624,"startTime":"0","endTime":"0","summary":"Reports Q2 revenue $10.88M, consensus $12.73M. “Establishing ClearPoint Neuro (CLPT) as the leading neuro cell and gene therapy delivery company ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","JDOC","LFSC","CNCR","BK4082","BK4588","SYNB","IBBQ","IDNA","WDNA","FBT","IBB","BK4585","TBXU","CLPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656083301","title":"ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656083301","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656083301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:14","pubTimestamp":1785788065,"startTime":"0","endTime":"0","summary":"ClearPoint Neuro Q2 revenue rises 18% but misses estimatesOverviewDevice and gene therapy-enabling firm's Q2 revenue rose 18% yr/yr but missed analyst expectationsGross margin improved to 62% from 60%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HELX","CLPT","KRYS","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301205","title":"GeneDx Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301205","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301205?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:12","pubTimestamp":1785787943,"startTime":"0","endTime":"0","summary":"GeneDx Q2 revenue beats analyst estimatesOverviewU.S. rare disease genomics tester's Q2 revenue grew 11% yr/yr, beating analyst expectationsAdjusted net income was $0.4 mln, up from a loss in the prio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","HELX","PSCH","BK4196","KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303023","title":"Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303023","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303023?lang=en_us&edition=fundamental","pubTime":"2026-08-04 01:25","pubTimestamp":1785777900,"startTime":"0","endTime":"0","summary":"Krystal Biotech, Inc.  is currently at $300.76, down $40.37 or 11.83%--Would be lowest close since June 2, 2026, when it closed at $293.21--On pace for largest percent decrease since Aug. 4, 2025, when it fell 14.04%--Currently down three of the past four days--Currently down two consecutive days; down 18.02% over this period--Worst two day stretch since the two days ending May 9, 2022, when it fell 21.35%--Up 21.99% year-to-date--Down 20.47% from its all-time closing high of $378.15 on June 29, 2026--Up 122.88% from 52 weeks ago , when it closed at $134.94--Down 20.47% from its 52-week closing high of $378.15 on June 29, 2026--Up 122.88% from its 52-week closing low of $134.94 on Aug. 4, 2025--Traded as low as $297.02; lowest intraday level since June 3, 2026, when it hit $290.04--Down 12.93% at today's intraday low; largest intraday percent decrease since Aug. 4, 2025, when it fell as much as 16.87%All data as of 1:20:00 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","BK4139","KRYS","BK4585","XBI","PSCH","HELX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}